Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul...
Transcript of Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul...
![Page 1: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/1.jpg)
Controversies in Neurocritical Care
Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery
Director of Neurocritical Care
UCLA David Geffen School of Medicine
![Page 2: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/2.jpg)
Agenda
• Carotid Intervention in Carotid Artery Stenosis
– CEA vs CAS ?
• Acute Stroke Thrombectomy in 2014
– Should we be doing it?
• Blood Pressure control in Intracerebral hemorrhage
– What is the best number?
![Page 3: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/3.jpg)
Carotid Stenosis
![Page 4: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/4.jpg)
Options: CEA and CAS
![Page 5: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/5.jpg)
Outcome of CEA based on degree of
stenosis
![Page 6: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/6.jpg)
Indications for CEA based on NASCET
![Page 7: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/7.jpg)
Carotid Angioplasty and Stenting
(CAS) in carotid stenosis
![Page 8: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/8.jpg)
• N = 167 CAS vs N = 167 CEA
• Carotid ultrasound to make stenosis
• 1:1 randomization
• 81 or 325 mg ASA
• Nitinol stent with emboli prevention
device
• Little details about CEA – “ surgeons
used their customary techniques”
SAPPHIRE
![Page 9: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/9.jpg)
SAPPHIRE
![Page 10: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/10.jpg)
Critique of SAPPHIRE
• Mixture of Asx and Symptomatic
• Outcome is a gamish of all M+M
• No functional outcome data
– No QOL or mRS, etc
• CEA arm may not have been well controlled,
outcome is not comparable with NASCET
![Page 11: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/11.jpg)
![Page 12: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/12.jpg)
CREST 2010
![Page 13: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/13.jpg)
CREST 2010
![Page 14: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/14.jpg)
Summary of published trials in CAS vs CEA
![Page 15: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/15.jpg)
Safety of CEA is better than CAS Silver et al Stroke 2011
CEA CAS Symptomatic
CEA CAS Asymptomatic
![Page 16: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/16.jpg)
Abbott et al
![Page 17: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/17.jpg)
![Page 18: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/18.jpg)
![Page 19: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/19.jpg)
![Page 20: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/20.jpg)
Cerebral Hyperperfusion after CEA
Komorobashyi JCBFM 2005
![Page 21: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/21.jpg)
Controversy regarding Thrombectomy in acute stroke
• Within 4.5 hours, IV tpa is reasonable for most patients
– Old age >80, diabetes and hypertension, warfarin
• Beyond 4.5 hours, the possibility of intra-arterial therapy exists
– IA tpa
– Thrombectomy
![Page 22: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/22.jpg)
![Page 23: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/23.jpg)
Synthesis Results Italian study using the Penumbra Device
ET (n=181) IVT (n=181)
Onset to randomization 2:28 (2:04-3:10 2:25 (1:59-2:59)
Onset to treatment* 3:45 (3:14-4:20) 2:45 (2:20-3:20)
UCLA Stroke Center
![Page 24: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/24.jpg)
![Page 25: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/25.jpg)
MR Rescue Trial – thrombectomy in mismatch cohort
Tmax PWI Predictive
Map
Day 7
Infarct
Favorable
Penumbral
Pattern
Non-Penumbral
Pattern
DWI
Favorable = predicted infarct core ≤ 90 cc & ratio of predicted infarct tissue
within at-risk region ≤ 70% (voxel-based multivariate MRI and CT models)
Kidwell et al, Stroke 2012
![Page 26: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/26.jpg)
MR Rescue results
Primary Hypothesis: Test for Interaction between treatment assignment and
penumbral pattern by shift analysis
E/Pen n=34
S/Pen n=34
E/Non-Pen n=30
S/Non-Pen n=20
p value
Mean (95% CI) Day 90 mRS 3.9
(3.3-4.4) 3.4
(2.8-4.0) 4.0
(3.4-4.6) 4.4
(3.6-5.2) 0.14
As such, the trial failed to demonstrate that penumbral imaging identifies
patients who will differentially benefit from endovascular therapy for acute
ischemic stroke
![Page 27: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/27.jpg)
JL Saver, R Jahan, E Levy, T G Jovin, B Baxter, R Nogueira, W Clark, R Budzik, OO Zaidat, for
the SWIFT Trialists
Lancet, Aug 26, 2012
![Page 28: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/28.jpg)
Clinical Outcomes
Outcomes Among
Randomized Patients
Randomized
Solitaire FR
N=58
Randomized
Merci
N=55
Non-
inferiority
P value1
Superiority
P value1
Good neurologic outcome
at 90d2 58.2% (32/55) 33.3% (16/48) 0.0001 0.017
Mortality at 90 days 17.2% (10/58) 38.2% (21/55) 0.0001 0.020
1. Noninferiority by Wald’s method, superiority by Fisher’s Exact test
2. Good neurological outcome defined as mRS ≤ 2, or equal to the prestroke mRS if the prestroke mRS was higher than 2, or NIHSS score improvement ≥ 10
Tim
e to
Dea
th
P=0.014
(Days)
![Page 29: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/29.jpg)
Blood Pressure control in ICH
Stroke 2007; Stroke 2010
![Page 30: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/30.jpg)
ICH patient with hypertension, instability early on
0
50
100
150
200
250
8:0
0
10:0
0
12:0
0
14:0
0
16:0
0
18:0
0
20:0
0
22:0
0
0:0
0
2:0
0
4:0
0
6:0
0
8:0
0
Hour
SB
P m
m H
g
![Page 31: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/31.jpg)
![Page 32: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/32.jpg)
Interact 1: median 4 hours to start of treatment
![Page 33: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/33.jpg)
Interact 1 results
![Page 34: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/34.jpg)
Interact results
![Page 35: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/35.jpg)
INTERACT 2 - Slides are courtesy of Craig Anderson Feb 15, 2014
![Page 36: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/36.jpg)
Protocol schema from INTERACT1 (Lancet Neurol 2008) and INTERACT 2 (Int J Stroke 2010)
Acute spontaneous ICH confirmed by CT/MRI
Definite time of onset within 6 hours
Systolic BP 150 to 220 mmHg
No indication/contraindication to treatment
In-hospital vital signs, NIHSS, GCS and BP over 7 days
Intensive BP lowering
SBP <140 mmHg
Standard BP management
Guidelines SBP <180 mmHg)
R
36
Independent 90 day outcome with modified Rankin scale (mRS)
POWER CALCULATION FOR INTERACT 2
N=2800 gives 90% power for 7% absolute (14% relative) decrease (50% standard vs 43% intensive) in outcome
Patients were excluded with large ICH, poor prognosis, early surgery
Lots of patients got mannitol ATC
![Page 37: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/37.jpg)
INTERACT2 – Small hematomas were studied
0 10 20 30 40 50 60 70 80 90 100
0.6
0.4
0.2
0
Density
Baseline hematoma volume (ml)
median Surgery
threshold
![Page 38: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/38.jpg)
Systolic BP time trends 1 hour - Δ14 mmHg (P<0.0001) 6 hour - Δ14 mmHg (P<0.0001)
Systolic BP control Median (iqr) time to treatment, hr - intensive 4 (3-5), standard 5 (3-7)
Intensive group to target (<140mmHg) 462 (33%) at 1 hour 731 (53%) at 6 hours
Me
an
Systo
lic B
loo
d P
ressu
re (
mm
H
g)
0
110
120
130
140
150
160
170
180
190
200
R 15 30 45 60 6 12 18 24 2 3 4 5 6 7
Standard Intensive
// //
Minutes Hours Days / Time
164
153
150
139
am pm am pm am pm am pm am pm am pm
P<0.0001
beyond 15mins
Target level
38
![Page 39: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/39.jpg)
Primary clinical outcome
Death or major disability (mRS 3-6) at 90 days
12.0 12.0
40.0 43.6
0
10
20
30
40
50
60
Intensive Standard
Major Disability
(3-5)
Death (6)
%
(N=1399) (N=1430)
52.0% 55.6%
Odds ratio 0.87 (95%CI 0.75 to 1.01) P=0.06
39
![Page 40: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/40.jpg)
Key secondary outcome Ordinal shift in mRS scores (0-6)
Odds ratio 0.87 (95%CI 0.77 to 1.00); P=0.04
40
18.0%
18.8%
16.6%
19.0%
\
12.0%
8.0%
0 1 2 3 4 5 6
Intensive
Standard
Major disability Death Disability but independent
18.7% 15.9% 18.1% 6.0% 21.1% 8.1% 12.0%
7.6%
![Page 41: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/41.jpg)
Interact 2 – hemorrhagic expansion was the same in both groups
![Page 42: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/42.jpg)
Systo
lic B
lood P
ressure
(m
mH
g)
21.5
20.1 19.2
19.7 18.7 19.4 19.3 19.3 19.1
18.9 19.2 19.3 18.9 18.5 18.1 18.6 18.5 20.8
18.4 17.7 17.6 16.9 16.7
17.2 18.1 17.6 17.4 16.9
17.5 16.7 16.4 16.4 16.3 16.6
12
0
14
0
16
0
18
0
20
0
1 6 12 18 24 am pm am pm am pm am pm am pm am pm
Guideline group
Intensive group
Hour Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
![Page 43: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/43.jpg)
BP variability is associated with worsened outcome in INTERACT 2
![Page 44: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/44.jpg)
Interpretation of Interact 2
• Study of variable BP reduction
– 140 -145 mm Hg vs 150-155 range
• Primary outcome was negative (p =0.06)
• Secondary outcomes appear to be better in the intervention group (p < 0.04)
– Strong trend towards benefit across all categories
• BP variability is important
– less variability of BP correlates to better outcomes
![Page 45: Controversies in Neurocritical Care - Ogden Surgical · Controversies in Neurocritical Care Paul Vespa, MD, FCCM, FAAN, FNCS Professor of Neurology and Neurosurgery Director of Neurocritical](https://reader030.fdocuments.us/reader030/viewer/2022041109/5f0cc4757e708231d4370810/html5/thumbnails/45.jpg)
Conclusions
• CEA is best for carotid stenosis
– CAS may be reasonable alternative
• Thrombectomy for acute stroke is unproven
– Novel devices now being tested
• BP control for ICH 100-150 seems reasonable based on data
– Special attention to avoiding BP fluctuations